1121 GMT - Roche's Genentech acquisition of Regor Pharmaceuticals' CDK inhibitors opens up a combination potential with its experimental hormone therapy drug for breast cancer Giredestrant, Barclays analysts say in a note. The Swiss drugmaker's acquired CDK portfolio--used to treat cancers by preventing overproliferation of cancer cells--should expand its treatment options for advanced breast cancer, they say. "We see this as a sensible bolt-on deal for Roche in oncology and would imagine the company's intention would be to explore combinations with giredestrant," the analysts say. Shares fall 0.1%. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
September 30, 2024 07:21 ET (11:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.